Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20472582 | 0.98 | GPR84 (0.65) | GPR84FFAR1CA1CA2FFAR4 | |
| SCHEMBL4957808 | 0.98 | GPR84 (0.65) | GPR84FFAR1CA1CA2FFAR4 | |
| SCHEMBL5575803 | 0.98 | GPR84 (0.65) | GPR84FFAR1CA1CA2FFAR4 | |
| SCHEMBL15007853 | 0.98 | GPR84 (0.65) | GPR84FFAR1CA1CA2FFAR4 | |
| SCHEMBL3761975 | 0.98 | GPR84 (0.65) | GPR84FFAR1CA1CA2FFAR4 | |
| SCHEMBL15007874 | 0.98 | GPR84 (0.65) | GPR84FFAR1CA1CA2FFAR4 | |
| SCHEMBL4850662 | 0.98 | GPR84 (0.65) | GPR84FFAR1CA1CA2FFAR4 | |
| SCHEMBL34950 | 0.98 | GPR84 (0.65) | GPR84FFAR1CA1CA2FFAR4 | |
| SCHEMBL13849594 | 0.98 | GPR84 (0.65) | GPR84FFAR1CA1CA2FFAR4 | |
| SCHEMBL5575801 | 0.98 | GPR84 (0.65) | GPR84FFAR1CA1CA2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043165-A1 | LOW-TEMPERATURE CURING COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240294780-A1 | ELECTRODEPOSITABLE COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2024-05-30 | — | — | US | disclosed |
| EP-4363511-A1 | ELECTRODEPOSITABLE COATING COMPOSITIONS | PPG Industries Ohio Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-3580290-B1 | LOW-TEMPERATURE CURING COATING COMPOSITIONS | PPG IND OHIO INC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11952514-B2 | Low-temperature curing adhesive compositions | PPG INDUSTRIES OHIO, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2023279087-A1 | ELECTRODEPOSITABLE COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| CN-112375105-B | Application of N, N-coordinated divalent nickel complex containing meta-carborane ligand | 上海应用技术大学 | 2022-08-23 | — | — | CN | disclosed |
| CN-113646172-A | Laminated body | 宇部兴产株式会社 | 2021-11-12 | — | — | CN | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| EP-1581510-A2 | 1-ARYL-2-HYDROXYETHYL AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581510-A2 | 1-ARYL-2-HYDROXYETHYL AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050009921-A1 | Compounds having aromatic rings and side-chain amide-functionality and a method for transporting monovalent anions across biological membranes using the same | MARYLAND, UNIVERSITY OF | 2005-01-13 | — | — | US | disclosed |
| WO-2004110989-A1 | N-HYDROXY-7-(ARYLAMINO)HEPTANAMIDE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004047743-A3 | 1-ARYL-2-HYDROXYETHYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL MYERS SQUIBB CO (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2004047743-A2 | 1-ARYL-2-HYDROXYETHYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004047743-A2 | 1-ARYL-2-HYDROXYETHYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| CN-87105781-A | ANTIMICROBIAL MIXTURES | — | 1988-03-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | KCNQ3, KCNQ2, KCNQ4 | GPR84 503/4885FFAR1 212/4885CA1 1173/4885 |
| US-20050009921-A1 | Compounds having aromatic rings and side-chain amide-functionality and a method for transporting monovalent anions across biological membranes using the same | SLC26A3, SLC22A8, SLC43A1 | GPR84 1156/4885FFAR1 1701/4885CA1 1259/4885 |
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | GPR84 2967/4885FFAR1 4405/4885CA1 4209/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | GPR84 2967/4885FFAR1 4405/4885CA1 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.